Diagnostic marker of clear cell renal cell carcinoma-c16orf74 gene

A technology of renal clear cell carcinoma and gene, applied in the field of biomedicine, can solve the problems of unsatisfactory immunotherapy effect, limited curative effect, and 5-year survival rate of less than 10%

Active Publication Date: 2019-07-09
THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Like other types of RCC, cc-RCC is not sensitive to radiotherapy, chemotherapy and hormone therapy, and the effect of immunotherapy is not satisfactory. In recent years, some progress has been made in biological targeted therapy for advanced renal cancer, but the curative effect is still very limited
Surgical resection is still the main treatment at present, and the 5-year survival rate of small, well-differentiated early cc-RCC without metastasis can reach 90%; but once metastasis occurs, the 5-year survival rate is less than 10%
Current research shows that the occurrence and development of renal cell carcinoma is a multi-factor, multi-gene abnormality and multi-stage process, and the pathogenesis is extremely complex

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic marker of clear cell renal cell carcinoma-c16orf74 gene
  • Diagnostic marker of clear cell renal cell carcinoma-c16orf74 gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1 Screening of differentially expressed genes in renal clear cell carcinoma tissue

[0062] 1. Sample collection

[0063] The 5 cases were all ccRCC patients admitted to the urology department of the hospital. All 3 cancer tissue specimens were frozen in a liquid nitrogen tank 0.5h after radical renal resection, and 2 normal kidney tissue specimens were taken from the normal area of ​​T1 renal cancer that was more than 5cm away from the primary tumor. All specimens were confirmed by routine pathological examinations, and were reviewed again by the hospital pathology department before the experiment. The retention of experimental specimens was approved by patients or family members.

[0064] 2. Extraction of total RNA from sample

[0065] Take about 50-100 mg of each of the above-mentioned tissue samples, add Trizol to extract total RNA, use Beckman DU530 ultraviolet spectrophotometer to determine the concentration and purity of the samples, and then use Agilent BioAna...

Embodiment 2

[0075] Example 2 Verification of differentially expressed genes in large samples

[0076] The selection of high-throughput sequencing suggested that the differentially expressed C16orf74 gene between renal clear cell carcinoma tissue and normal kidney tissue was the research goal for large sample verification.

[0077] 1. Tissue acquisition and processing: According to the method in Example 1, 45 cases of renal clear cell carcinoma tissue and 45 cases of normal renal tissue were collected.

[0078] 2. RNA extraction

[0079] The RNA extraction was performed according to the method of Example 1.

[0080] 3. Reverse transcription synthesis of cDNA

[0081] Take 2μg of total RNA each, add 5μl T7 promoter primer, add nuclease-free water to the total reaction volume to 11.5μl, water bath at 65℃ for 10min, place on ice for 5min, then add 8.5μl cDNA Master Mix (containing 5x first strand Buffer 4μl, 0.1mol / L DTT 2mol / L. 10mol / L dNTP mix 1μl, reverse transcriptase MMLV 1μl, RNase inhibitor 0.5μ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a C16orf74 gene which can be taken as a biomarker for the renal clear cell carcinoma. The experiment proves that compared with normal nephridial tissues, the C16orf74 gene expression in renal clear cell carcinoma tissues is significantly improved. According to the research result, the C16orf74 gene can be applied to research and development of a kit used for diagnosing therenal clear cell carcinoma and also can be used for researching and developing medicines capable of inhibiting the C16orf74 gene expression, thereby achieving clinical prevention and treatment for therenal clear cell carcinoma.

Description

Technical field [0001] The invention belongs to the field of biomedicine, and relates to a diagnostic marker for renal clear cell carcinoma, in particular to the use of the C16orf74 gene in the diagnosis of renal clear cell carcinoma. Background technique [0002] Renal cell carcinoma (RCC), also known as renal cell carcinoma, renal adenocarcinoma, adrenoid tumor, etc., is the most common renal parenchymal malignant tumor, accounting for 3% of human systemic malignancies, and its incidence is among urinary malignancies The second place. The incidence of RCC is increasing year by year in European and American countries. According to statistics, there are about 30,000 new RCC patients in the United States every year, and about 12,000 people die from RCC-related diseases every year. The incidence rate of kidney cancer is about 3.5:1 between men and women. It often occurs after 40 years old, and occasionally people under 30 years old. Renal cancer often originates from epithelial c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G01N33/574A61K45/00A61P35/00
CPCA61K45/00A61P35/00C12Q1/6886C12Q2600/158G01N33/57438G01N33/57484G01N2333/47
Inventor 周强申兵冰刘宏赵洪雯于艳杰梅玫徐小松
Owner THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap